Drugs Often Approved For Wider Use Than Tested, Says Swiss Study

(MENAFN- Swissinfo) A study led by a professor at the federal technology institute ETH Zurich has found that many medicines are approved for use in groups of people who weren't part of the clinical trials. This content was published on July 20, 2025 - 13:13 4 minutes SRF

+ Get the most important news from Switzerland in your inbox

People under 60, with no underlying health conditions or previous treatments – these are the kinds of patients typically included in clinical trials. Strict criteria mean only a narrow slice of the population is tested. That's a problem, because the effectiveness and side effects of a drug are only measured in this limited group.

However, medicines are often approved by regulatory authorities for use in a broader population than the one tested. A new study highlights just how common this gap is between who gets tested and who ends up taking the drug.

An international team of researchers, led by Kerstin Vokinger, Professor of Law and Medicine at the University of Zurich and ETH Zurich, has taken a closer look at how medicines are approved. They wanted to find out how often the people tested in clinical trials differ from those who end up being prescribed the drugs.

+ Drugmakers are finally making medicine for women

The team analysed all 278 medicines approved between 2012 and 2023 across Switzerland, the European Union (EU), and the United States (US). The findings are striking.

Medicines often approved for broader use than tested

In Switzerland, for example, 14.7% of medicines were approved for age groups that hadn't been included in the clinical trials.

One case involved a melanoma drug trial that excluded people with heart conditions or organ damage. Despite that, the drug was later approved for patients with exactly those health issues.

In every category examined, and across all three regulatory authorities, medicines were consistently approved for broader use than they had been tested for. The most pronounced differences were seen in what researchers refer to as“patient fitness” – meaning patients' overall health or general well-being. In nearly every case, there were mismatches.

People who received the approved drugs were often in significantly poorer health than those in the trial groups.

“These patient groups weren't part of the trials. That makes it hard to predict how well the medicine will work or what side effects might appear,” says Vokinger.

More More Swiss regulator and media clash over weight-loss drugs

This content was published on Jan 21, 2025 Swissmedic has taken legal action against media for alleged unauthorised advertising of weight-loss drugs. Swiss media say this is censorship.

Read more: Swiss regulator and media clash over weight-loss drug

MENAFN20072025000210011054ID1109823661